PDF(Pubmed)
Abstract：
The utilization of actinium-225 (225Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225Ac production methods, various preclinical investigations, and several clinical studies. Currently, there is a growing number of compounds labeled with 225Ac that are being developed and tested in clinical trials. In response to the increasing demand for this nuclide, production facilities are either being built or have already been established. This article offers a concise summary of the present state of clinical advancements in compounds labeled with 225Ac. It outlines various processes involved in the production and purification of 225Ac to cater to the growing demand for this radionuclide. The article examines the merits and drawbacks of different procedures, delves into preclinical trials, and discusses ongoing clinical trials.
摘要：
1993年最初概述了在癌症的靶向α治疗中使用Act-225（225Ac）放射性核素。在过去的二十年里，已经进行了大量研究，包括建立225Ac的生产方法，各种临床前调查，和一些临床研究。目前,越来越多的用225Ac标记的化合物正在开发和临床试验中进行测试。为了应对这种核素日益增长的需求，生产设施正在建设或已经建立。本文简要概述了用225Ac标记的化合物的临床进展的现状。它概述了225Ac的生产和纯化过程，以满足对这种放射性核素日益增长的需求。文章考察了不同程序的优缺点,深入研究临床前试验，并讨论正在进行的临床试验。
